相似文献
1
Treatment of saphenous vein graft disease: "never ending story" of the "eternal return".
Res Cardiovasc Med. 2014 Aug;3(3):e21092. doi: 10.5812/cardiovascmed.21092. Epub 2014 Jul 28.
2
Contemporary Use of Embolic Protection Devices During Saphenous Vein Graft Intervention.
Circ Cardiovasc Interv. 2019 May;12(5):e007636. doi: 10.1161/CIRCINTERVENTIONS.118.007636.
3
Embolic Protection Devices for Saphenous Vein Graft Percutaneous Coronary Interventions.
Interv Cardiol Clin. 2013 Apr;2(2):259-271. doi: 10.1016/j.iccl.2012.11.008. Epub 2013 Feb 12.
4
Embolic Protection Devices in Saphenous Vein Graft Intervention.
Circ Cardiovasc Interv. 2019 May;12(5):e007879. doi: 10.1161/CIRCINTERVENTIONS.119.007879.
5
Morphometric analysis of particulate debris extracted by four different embolic protection devices from coronary arteries, aortocoronary saphenous vein conduits, and carotid arteries.
Am J Cardiol. 2005 Jun 15;95(12):1415-9. doi: 10.1016/j.amjcard.2005.02.006.
6
Saphenous vein bypass graft intervention and embolic protection devices: Time for reassessment (and revision of percutaneous coronary intervention guidelines).
Catheter Cardiovasc Interv. 2016 Jul;88(1):84-5. doi: 10.1002/ccd.26638.
7
Saphenous vein graft interventions: strategies and devices to minimize distal embolization.
Minerva Cardioangiol. 2012 Apr;60(2):157-66.
8
Embolic Protection Devices in Saphenous Vein Graft Intervention: A Stitch in Time Saves Nine.
Circ Cardiovasc Interv. 2017 Dec;10(12). doi: 10.1161/CIRCINTERVENTIONS.117.006124.
9
Embolic Protection Devices in Vein Graft Interventions: What Would You Do?
JACC Cardiovasc Interv. 2019 Nov 25;12(22):2296-2298. doi: 10.1016/j.jcin.2019.09.017.
10
The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial.
J Am Coll Cardiol. 2007 Oct 9;50(15):1442-9. doi: 10.1016/j.jacc.2007.06.039. Epub 2007 Sep 24.
本文引用的文献
1
Early and midterm major adverse cardiac events in patient with saphenous vein graft using direct stenting or embolic protection device stenting.
Res Cardiovasc Med. 2014 Feb;3(1):e13012. doi: 10.5812/cardiovascmed.13012. Epub 2014 Feb 24.
2
Five-year follow-up of the plaque sealing with paclitaxel-eluting stents vs medical therapy for the treatment of intermediate nonobstructive saphenous vein graft lesions (VELETI) trial.
Can J Cardiol. 2014 Jan;30(1):138-45. doi: 10.1016/j.cjca.2013.11.002. Epub 2013 Nov 6.
3
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
Catheter Cardiovasc Interv. 2012 Feb 15;79(3):453-95. doi: 10.1002/ccd.23438.
4
5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial.
JACC Cardiovasc Interv. 2011 Mar;4(3):300-9. doi: 10.1016/j.jcin.2010.11.013.
5
Clinical and angiographic outcomes after percutaneous recanalization of chronic total saphenous vein graft occlusion using modern techniques.
Am J Cardiol. 2010 Dec 15;106(12):1721-7. doi: 10.1016/j.amjcard.2010.08.013. Epub 2010 Oct 26.
6
Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis.
EuroIntervention. 2010 Sep;6(4):527-36. doi: 10.4244/EIJ30V6I4A87.
7
Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators).
Am J Cardiol. 2010 Oct 1;106(7):941-5. doi: 10.1016/j.amjcard.2010.06.003. Epub 2010 Aug 17.
8
Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
JACC Cardiovasc Interv. 2009 Nov;2(11):1105-12. doi: 10.1016/j.jcin.2009.08.020.
9
Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients.
Circulation. 2008 Feb 12;117(6):790-7. doi: 10.1161/CIRCULATIONAHA.106.651232. Epub 2008 Jan 22.
10
Pivotal, randomized U.S. study of the Symbiottrade mark covered stent system in patients with saphenous vein graft disease: eight-month angiographic and clinical results from the Symbiot III trial.
Catheter Cardiovasc Interv. 2006 Sep;68(3):379-88. doi: 10.1002/ccd.20873.
Zotero 插件